Extrait

The primary objective of this study is to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical antipsychotic standard-of-care treatment.

Critère d'inclusion

• Schizophrenia

Liens

• euctr
• ictrp